Abstract: The present invention relates to compounds containing organofluorochlorophosphate anions, the preparation thereof and the use thereof, in particular as ionic liquids.

Abstract: The invention provides methods for preparing polymers bearing a terminal propionic acid. The method involves first reacting a water soluble and non-peptidic polymer comprising at least one hydroxyl group with a tertiary alkyl acrylate in the presence of a catalyst to form a propionic acid ester of the polymer, wherein the polymer has a weight average molecular weight of at least about 10,000 Da; and then treating the propionic acid ester of the polymer with a strong acid to form a propionic acid of the polymer.

Abstract: A method of isolating atipamezole hydrocloride as a crystalline salt is provided.

Abstract: The present invention relates to compounds of formula (Ia), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, R1, R2, R3 and R4 are as defined in the description and claims.

Abstract: There is provided compounds of formula (I), wherein X1, X2, X3, Y4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract: The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and; R2 is selected from the group consisting of H, C1-C4 alkyl, (C1-C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

Abstract: Novel phosphonium and imidazolium salts and methods for preparing them are disclosed. The novel phosphonium and imidazolium compounds are useful as polar solvents and have the general formula (I): Q+X? wherein Q+ is formula (a) or formula (b); and X? is formula (c), formula (d) or formula (e); and wherein: each of R1, R2, R3, R4, R5, R9, R10, R11, R12, and R13 is independently a hydrocarbyl group; each of R6, R7, and R8 is independently a hydrogen or hydrocarbyl group.

Abstract: The present invention provides a photochromic compound that is colored when irradiated with visible light and quickly faded when set in a dark place. The photochromic compound according to the present invention is expressed by the following general formula (I): where each of A1, A2 and A3 is a five-member rings forming a 6?-electron system, the three rings being identical, partially identical or totally different from each other, and each ring may have a substituent; B1 and B2 are functional groups, each having an atomic number of five or larger, including a ring compound, and bonded to the 2-carbon of each of A2 and A3, respectively; and R1, R2 and R3 are substituents identical to or different from each other. This compound is highly colorable and durable even when it is dispersed into plastic macromolecular materials. Therefore, it is suitable as a dye material for sunglasses or similar products.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: A method of preparing an ionic conducting gel in solid form, known as ionogel. The method includes a step of mixing an ionic liquid with at least one molecular precursor containing at least one hydrolyzable group, if necessary in the presence of an acid, such as a carboxylic acid. The mixture is subsequently left to stand for one or more days until a gel is formed by polycondensation of the molecular precursor(s). The gel contains the aforementioned ionic liquid and can be set, in particular in transparent monolithic solid form.

Abstract: A method for removing hydrocarbon impurities from acetic acid is disclosed. The method comprises extracting acetic acid with a hydrophilic imidazolium salt. The imidazolium salt preferably has the general structure of wherein X? is a counter ion and R1, R2, R3, R4, and R5 are independently selected from the group consisting of C1-C6 hydrocarbon substitutes. The method is useful for removing hydrocarbon impurities from the alkane distillation bottoms stream of a methanol carbonylation process.

Abstract: Aspects of the present invention relate to compositions and methods for the use of ionic liquids with dissolved metal compounds as catalysts for a variety of chemical reactions. Ionic liquids are salts that generally are liquids at room temperature, and are capable of dissolving a many types of compounds that are relatively insoluble in aqueous or organic solvent systems. Specifically, ionic liquids may dissolve metal compounds to produce homogeneous and heterogeneous organometallic catalysts. One industrially-important chemical reaction that may be catalyzed by metal-containing ionic liquid catalysts is the conversion of methane to methanol.

Abstract: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy.

Abstract: The invention relates to a process for the preparation of onium salts with dialkylphosphate, dialkylphosphinate or (O-alkyl)alkyl- or alkylphosphonate anions by reaction of an onium halide with a triallyl phosphate, alkyl dialkylphosphinate, dialkyl alkylphosphonate or trialkylsilyl ester or mixed alkyl trialkylsilyl ester of phosphoric, dialkylphosphinic or alkylphosphonic acid.

Abstract: The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.

Abstract: The invention relates to a method for producing onium salts comprising alkyl anions or aryl sulfonate anions or alkyl carboxylate anions or acryl carboxylate anions by reacting an onium halide with an alkyl silyl ester or trialkyl silyl ester of an alkyl sulfonic acid or aryl sulfonic acid or an alkyl carboxylic acid or aryl carboxylic acid or the anhydrides thereof.

Abstract: The present invention provides a process for the preparation of imidazoles by reacting a cyano compound with a silylalkylisocyanide compound. Such imidazoles are useful pharmacologically-active compounds and/or intermediates for the preparation of pharmacologically-active compounds.

Abstract: A method of 4-substituted imidazole-2-ones and thiones which comprises reacting a methylene urea or methylene thiourea wherein said methylene is substituted with the 4-subsituent and a cyano or alkycarboxylate group to provide said 4-substituted imidazole 2-one or thione.

Abstract: The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Abstract: A method for producing a fluorine-containing organic compound represented by the formula (7): R—Fm??(7) wherein R represents a substituted or unsubstituted saturated hydrocarbon group, or a substituted or unsubstituted aromatic group and m represents an integer satisfying the inequality: 1?m?n, which comprises reacting a fluorinating agent represented by the formula (1): wherein R1 and R3 are the same or different, and represent an optionally substituted alkyl group, R2, R4 and R5 are the same or different, and represent a hydrogen atom or an optionally substituted alkyl group, x satisfies 0<x?1, and Y? represents a monovalent anion other than a fluoride ion, with an organic compound of the formula (6): R-Ln??(6) wherein R is the same as defined above, L represents a leaving group and n represents an integer of 1 or more, and a fluorinating agent using the same are described.

Abstract: Provided is a new organic-acid-based catalyst enabling production of a polyhydroxycarboxylic acid by direct dehydration polycondensation of a hydroxycarboxylic acid such as L-lactic acid, specifically, an organic-acid-based catalyst comprising an amine salt of a sulfonic acid or a phosphine salt of a sulfonic acid for production of polyhydroxycarboxylic acids such as poly-L-lactic acid.

Abstract: The invention provides heteroaryl salts and methods for producing the same. In particular, the invention provides heteroaryl salts of the formula: and methods for producing the same, where M, a, X1, X2, X3, and X4 are those defined herein.

Abstract: New phosphoramide derivatives of formula (I) and the salts and solvates thereof, wherein the meanings of the various substituents are as disclosed in the description. Said compounds are useful as antiinflammatory and analgesic agents.

Abstract: A one-pot industrial process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one of Formula-(I) from 1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one of Formula-(IV) involves reaction of Formula (IV) with HNR1R2 salt and paraformaldehyde, where R1,R2 are independently alkyl groups or together forms a cyclic alkyl group, in a solvent system of acetic acid and hydrocarbon solvent to form a crude mixture of intermediate compounds of Formula (III) and (VIII), which is converted to ondansetron (Formula (I)) without isolation by reaction with 2methyimidazole in a suitable solvent system in the same pot.

Abstract: Compositions of matter useful as ionic liquids of the formula Z+A?, wherein Z+ is a cation selected from the group consisting of pyridinium, pyridazinium, pyrimidinium, pyrazinium, imidazolium, pyrazolium, thiazolium, oxazolium, triazolium, and phosphonium, ammonium cations with specified substituents, and A? is selected from the group consisting of the following three anions wherein R11, R12 and R13 are as specified. R11—CHF—CF2—SO3???Formula I R12—CF2—CF2—SO3???Formula II (R13—CHF—CF2—SO2)2N???Formula III.

Abstract: Low melting ionic compounds of the general formula (cation) (R?SO4) in which R? is a branched or linear, saturated or unsaturated, aliphatic or alicyclic functionalized or non-functionalized hydrocarbon chain with 3-36 carbon atoms are provided. These compounds can serve as ionic liquids, e.g. as solvents or solvent additives in chemical reactions, as extraction agents or as heat carriers. The compounds comprise a cation and anionic sulfate ester.

Abstract: A novel imidazolium compound represented by the following general formula (I), which has an allyl group incorporated in the 3-position of the imidazolium ring. It needs no complicated operations for dissolution and has excellent handleability and a high ionic conductivity.

Abstract: The present invention is directed to the preparation of novel compounds useful in the treatment of hyperlipidemia, arteriosclerosis, hypercholesterolemia, and other related metabolic disorders. More specifically, the present invention is a novel process for the preparation of 1,4-diphenylazetidinone derivatives from ?-substituted amino amides which are protected in the presence of silylating agents and at least one cyclization catalyst whose structural formula is represented by one of the general formula: wherein the various R-groups are defined herein.

Abstract: The present invention relates to oxonium salts having [(Ro)3O]+ cations and sulfonium salts having [(Ro)3S]+ cations, where Ro denotes straight-chain or branched alkyl groups having 1-8 C atoms or phenyl which is unsubstituted or substituted by Ro, ORo, N(Ro)2, CN or halogen, and anions selected from the group of [PFx(CyF2y+1?zHz)6?x]? anions, where 2?x?5, 1?y?8 and 0?z?2y+1, or anions selected from the group of [BFn(CN)4?n]? anions, where n=0, 1 , 2 or 3, or anions selected from the group of [(Rf1SO2)2N]? anions or anions selected from the group of [BFwRf24?w]? anions, to processes for the preparation thereof, and to the use thereof, in particular for the preparation of ionic liquids.

Abstract: Resin compositions which contain a compound having at least two epoxy and/or thiirane groups in the molecule (ingredient (1)) and a specific ionic liquid (ingredient (2)), as combined, are practicable resin compositions which comprise constitutive elements of readily available materials and have well-balanced suitable curing capability and storage stability. Preferably, the ionic liquid (ingredient (2)) comprises a combination of an ammonium cation or phosphonium cation and a carboxylate anion.

Abstract: Method of separating acids from reaction mixtures by means of an auxiliary base, where the auxiliary base b) reacts with the acid to form a salt which is liquid at temperatures at which the desired product is not significantly decomposed while the liquid salt is being separated off and c) the salt of the auxiliary base forms two immiscible liquid phases with the desired product or the solution of the desired product in a suitable solvent, in which the auxiliary base used is an alkylmidazole, which has a solubility in 30% strength by weight sodium chloride solution at 25° C. of 10% by weight or less and whose hydrochloride has a melting point below 55° C.

Abstract: The present invention relates to imidazole derivatives of formula I wherein R1, R2, R3, R4, X, Y and R are described hereinabove, or a pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition comprising the imidazole derivatives of formula I, a process for preparing a compound of formula I, and a method of treating or preventing acute and/or chronic neurological disorder comprising administering to a patient in need of such treatment and/or prevention a therapeutically effective amount of said pharmaceutical composition. These disorders include Alzheimer's disease. These disorders also include mild cognitive impairment.

Abstract: This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Abstract: Compounds of the general formulae (I) and (II): where R1, R2 and R3 each independently of one another are H; C1-17alkyl; C3-12cycloalkyl, optionally substituted by C1-4alkyl groups; C4-20cycloalkyl-alkyl, optionally substituted by C1-4alkyl groups; C6-10, aryl, optionally substituted by 1-3 C1-4alkyl groups, —CN, Hal, OH, or C1-10alkoxy; C7-15phenylalkyl, optionally substituted by 1-3 C1-4alkyl groups; C3-12alkenyl; C3-12alkynyl; or aromatic or aliphatic C3-12acyl; R4, R5, R6, R7, R8, and R9 each independently of one another are H; C1-17alkyl, C3-12cycloalkyl, optionally substituted by C1-4alkyl groups; C4-20cycloalkyl-alkyl, optionally substituted by C1-4alkyl groups; C6-10aryl, optionally substituted by 1-3 C1-4alkyl groups; C7-15phenylalkyl, optionally substituted by 1-3 C1-4alkyl groups; C3-17alkenyl; C3-12alkynyl; C1-12alkoxy; or OH; for formula (1) R is C1-12alkyl; C3-12cycloalkyl, optionally substituted by C1-4alkyl groups; C4-20cycloalkyl-alkyl; optionally substituted by C1-4alkyl groups; C6-10aryl, o

Abstract: Certain imidazole compounds are CCK1 modulators useful in the treatment of CCK1 mediated diseases.

Abstract: The present invention describes a process for preparing ionic liquids (I) by reacting ionic liquids (II) whose anion is a halide with an acid (III), with the resulting hydrogen halide being scavenged by means of an amine and the resulting ammonium halide being able to be separated off.

Abstract: A fragment-based strategy, involving “multicomponent reaction chemistry” (MCR), can identify novel chemotypes that disrupt the p53/MDM2 or p53/MDM4 complex employs. This approach uses high resolution structural information to delineate the region of a first protein or a ligand that is nestled within the binding pocket of a second target protein. The identified region is imported into a database containing MCR scaffolds to generate a virtual library of compounds, which subsequently are docked into the binding pocket of the target protein. Results from docking then are used to select compounds for synthesis and screening. A complementary, NMR-based methodology allows for screening the ability of compounds, selected using MCR, to disrupt the p53/MDM2 or p53/MDM4 complex.

Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.

Abstract: A method of isolating atipamezole hydrochloride as a crystalline salt is provided.

Abstract: The invention concerns novel ionic compounds with low melting point whereof the onium type cation having at least a heteroatom such as N, O, S or P bearing the positive charge and whereof the anion includes, wholly or partially, at least an ion imidide such as (FX1O)N?(OX2F) wherein X1 and X2 are identical or different and comprise SO or PF, and their use as solvent in electrochemical devices. Said composition comprises a salt wherein the anionic charge is delocalised, and can be used, inter alia, as electrolyte.

Abstract: The invention relates to a process for the preparation of onium alkylsulfites by reaction of an onium halide or carboxylate with a symmetrically substituted dialkyl sulfite or with an asymmetrically substituted dialkyl sulfite at temperatures of 0 to 70° C.

Abstract: The present invention generally provides compositions including carbon-containing molecules, and related methods. In some cases, the present invention relates to aromatic molecules comprising functional groups bonded to the aromatic portion of the molecule, including nonplanar portions of the molecules. Methods of the invention may provide the ability to introduce a wide range of functional groups to carbon-containing molecules. In some cases, methods of the invention may be performed using relatively mild reaction conditions, such as relatively low temperature, low pressure, and/or in the absence of strong acids or strong bases. The present invention may provide a facile and modular approach to synthesizing molecules that may be useful in various applications including photovoltaic devices, sensors, and electrodes (e.g., for electrocatalysis).

Abstract: The invention relates to a process for the preparation of onium alkylsulfonates by reaction of an onium halide or carboxylate with a symmetrically substituted dialkyl sulfite or with an asymmetrically substituted dialkyl sulfite at temperatures of 50 to 170° C.

Abstract: The present invention relates to ionic liquids of low viscosity and high electrochemical stability, in particular for use in the area of electrochemistry and as solvents for carrying out chemical reactions.

Abstract: Ionic liquids and processes and apparatus for their production. The ionic liquids can be low sulfur and low halide carboxylated ionic liquids. The ionic liquids can be produced via formation of at least one intermediate carboxylated ionic liquid, and thereafter subjecting the intermediate carboxylated ionic liquid to at least one anion exchange process.

Abstract: This invention relates to a class of compounds having the general formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Abstract: The invention relates to a “push-pull” type compound, used for manufacturing polymer materials having both electrical conduction and photochromic properties, which responds to the general formula A-X-R in which: A is an electron acceptor group; X is a group having a ?-conjugated system and forms a photochromic group with A; and R is a polymerizable electron-donor group that is chosen among the carbazole group and the groups derived from the carbazole group by substitution, and which is linked to X by the nitrogen atom of the carbazole group. The invention also relates to an electroconducting and photochromic polymer material, obtained by polymerization of this compound. Applications: optoelectronics, signal processing, data storage, etc.

Abstract: The present invention relates to compounds of formula I, wherein X is —CH2— or —NH—; Y is —CH(lower alkoxy)-, —CH(lower alkyl)-, —O—, —S—, —S(O)—, —S(O)2— or —CH2—; and Ar is phenyl or naphthyl, which rings are optionally substituted by one or two substituents selected from the group consisting of halogen, lower alkoxy, lower alkyl and lower alkyl substituted by halogen; or a pharmaceutically-acceptable acid-addition salt thereof; with the proviso that, when X is —NH—, Y is —CH(lower alkyl)- or —CH2—; and the further proviso that the compound is not 2-phenethyl-1H-imidazole hydrochloride, 2-(3,4-dichloro-phenoxymethyl)-1H-imidazole hydrochloride, 2-(2-chloro-phenoxymethyl)-1H-imidazole hydrochloride, 2-(2,3-dichloro-phenoxymethyl)-1H-imidazole, benzyl-(1H-imidazol-2-yl)-amine, (4-chloro-benzyl)-(1H-imidazol-2-yl)-amine, or (2-chloro-benzyl)-(1H-imidazol-2-yl)-amine.

Abstract: The present invention relates to a novel proton-conducting polymer membrane based on polyazoles which can, because of its excellent chemical and thermal properties, be used in a variety of ways and is particularly useful as polymer electrolyte membrane (PEM) to produce membrane electrode units for PEM fuel cells.

Abstract: A process for producing heterocyclic compounds which are useful as pesticides, drugs, fungicidal materials or intermediates thereof. TosMIC is reacted with an aldehyde or an imino compound: 1) in a solvent mixture of an aprotic solvent with a protic solvent in the presence of a base, 2) in the presence of a phase-transfer catalyst and an inorganic base, or 3) in the presence of an inorganic base. Thus, a desired product can be efficiently obtained using a solution without isolating TosMIC which is irritating and unstable, has a low decomposition point and shows explosivity.